JPS61161298A - テトラペプチド、その製造法およびそれらを含有する調剤組成物 - Google Patents

テトラペプチド、その製造法およびそれらを含有する調剤組成物

Info

Publication number: JPS61161298A
Authority: JP; Japan
Prior art keywords: lys; arg; dan; formula; compound according
Prior art date: 1985-01-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP61000483A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0229080B2 (2

Inventor

ミシエル　ビンセン

ジヨルジユ　ルモン

クロード　クドウヌツク

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ADIR SARL

Original Assignee

ADIR SARL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-01-07

Filing date

1986-01-06

Publication date

1986-07-21

1986-01-06 Application filed by ADIR SARL filed Critical ADIR SARL

1986-07-21 Publication of JPS61161298A publication Critical patent/JPS61161298A/ja

1990-06-27 Publication of JPH0229080B2 publication Critical patent/JPH0229080B2/ja

Status Granted legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title description 6
239000003814 drug Substances 0.000 title description 2
238000004519 manufacturing process Methods 0.000 title 1
239000002253 acid Substances 0.000 claims abstract description 9
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
150000003839 salts Chemical class 0.000 claims abstract description 8
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 7
125000000217 alkyl group Chemical group 0.000 claims abstract description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 3
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims abstract description 3
SLBZCKMOHSBDJK-UHFFFAOYSA-N [amino-[amino-(hydroxymethylsulfanyl)-sulfanylmethyl]sulfinyl-sulfanylmethyl]sulfanylmethanol Chemical compound OCSC(S)(N)S(=O)C(N)(S)SCO SLBZCKMOHSBDJK-UHFFFAOYSA-N 0.000 claims abstract 2
150000001875 compounds Chemical class 0.000 claims description 37
238000000034 method Methods 0.000 claims description 18
241001465754 Metazoa Species 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
230000002519 immonomodulatory effect Effects 0.000 claims description 3
125000002947 alkylene group Chemical group 0.000 claims description 2
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
230000028993 immune response Effects 0.000 claims description 2
125000001288 lysyl group Chemical group 0.000 claims description 2
239000000126 substance Substances 0.000 claims 4
GYLMCBOAXJVARF-UHFFFAOYSA-N 3-azabicyclo[2.2.1]heptane Chemical compound C1C2CCC1NC2 GYLMCBOAXJVARF-UHFFFAOYSA-N 0.000 claims 1
KPUSZZFAYGWAHZ-UHFFFAOYSA-N 3-azabicyclo[2.2.2]octane Chemical compound C1CC2CCC1NC2 KPUSZZFAYGWAHZ-UHFFFAOYSA-N 0.000 claims 1
239000013543 active substance Substances 0.000 claims 1
YEDVUDDWJVRKIS-UHFFFAOYSA-N cyclopenta[b]pyrrole Chemical compound C1=C[C]2[N]C=CC2=C1 YEDVUDDWJVRKIS-UHFFFAOYSA-N 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
125000006302 indol-3-yl methyl group Chemical group [H]N1C([H])=C(C2=C([H])C([H])=C([H])C([H])=C12)C([H])([H])* 0.000 claims 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 28
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 22
239000012634 fragment Substances 0.000 description 12
238000004949 mass spectrometry Methods 0.000 description 12
239000002904 solvent Substances 0.000 description 10
-1 mercapto, methylthio, methylsulfoxide Chemical compound 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
238000001228 spectrum Methods 0.000 description 9
229910052799 carbon Inorganic materials 0.000 description 8
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 7
108010084754 Tuftsin Proteins 0.000 description 7
125000004433 nitrogen atom Chemical group N* 0.000 description 7
IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 7
229940035670 tuftsin Drugs 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000002585 base Substances 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000000284 extract Substances 0.000 description 3
RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
PDELQDSYLBLPQO-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indole Chemical compound C1CCCC2NCCC21 PDELQDSYLBLPQO-UHFFFAOYSA-N 0.000 description 2
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000588747 Klebsiella pneumoniae Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
125000001743 benzylic group Chemical group 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
229910052804 chromium Inorganic materials 0.000 description 2
239000011651 chromium Substances 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
230000000242 pagocytic effect Effects 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
229910052705 radium Inorganic materials 0.000 description 2
230000003595 spectral effect Effects 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
YMYLGVIBUGDMLT-MRVPVSSYSA-N (2r)-2-(phenylmethoxyamino)propanoic acid Chemical compound OC(=O)[C@@H](C)NOCC1=CC=CC=C1 YMYLGVIBUGDMLT-MRVPVSSYSA-N 0.000 description 1
QNRXNRGSOJZINA-QMMMGPOBSA-N (2s)-2,3-dihydro-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2N[C@H](C(=O)O)CC2=C1 QNRXNRGSOJZINA-QMMMGPOBSA-N 0.000 description 1
UNLYAPBBIOKKDC-SECBINFHSA-N (2s)-2-(phenylmethoxycarbonylamino)-3-sulfanylpropanoic acid Chemical compound OC(=O)[C@@H](CS)NC(=O)OCC1=CC=CC=C1 UNLYAPBBIOKKDC-SECBINFHSA-N 0.000 description 1
NSJDRLWFFAWSFP-NSHDSACASA-N (2s)-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CCC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 NSJDRLWFFAWSFP-NSHDSACASA-N 0.000 description 1
FCUKIMQZRWTDDP-SFHVURJKSA-N (2s)-2-[bis(phenylmethoxycarbonyl)amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C=1C=CC=CC=1COC(=O)N([C@@H](CCCNC(=N)N)C(O)=O)C(=O)OCC1=CC=CC=C1 FCUKIMQZRWTDDP-SFHVURJKSA-N 0.000 description 1
AHYFYYVVAXRMKB-KRWDZBQOSA-N (2s)-3-(1h-indol-3-yl)-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)OCC1=CC=CC=C1 AHYFYYVVAXRMKB-KRWDZBQOSA-N 0.000 description 1
FPKHNNQXKZMOJJ-NSHDSACASA-N (2s)-4-methylsulfanyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CSCC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 FPKHNNQXKZMOJJ-NSHDSACASA-N 0.000 description 1
OJTJKAUNOLVMDX-LBPRGKRZSA-N (2s)-6-amino-2-(phenylmethoxycarbonylamino)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 OJTJKAUNOLVMDX-LBPRGKRZSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
DIWCUPFNJXAUAE-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinolin-1-ium-2-carboxylate Chemical compound C1CCCC2NC(C(=O)O)CCC21 DIWCUPFNJXAUAE-UHFFFAOYSA-N 0.000 description 1
BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
WSMBEQKQQASPPL-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindole-1-carboxylic acid Chemical compound C1CCCC2C(C(=O)O)NCC21 WSMBEQKQQASPPL-UHFFFAOYSA-N 0.000 description 1
SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
229910014033 C-OH Inorganic materials 0.000 description 1
125000006519 CCH3 Chemical group 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229910014570 C—OH Inorganic materials 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
CJUMAFVKTCBCJK-UHFFFAOYSA-N N-benzyloxycarbonylglycine Chemical compound OC(=O)CNC(=O)OCC1=CC=CC=C1 CJUMAFVKTCBCJK-UHFFFAOYSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010089814 Plant Lectins Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical group CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229940095564 anhydrous calcium sulfate Drugs 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
238000009412 basement excavation Methods 0.000 description 1
230000008512 biological response Effects 0.000 description 1
DFFDSQBEGQFJJU-UHFFFAOYSA-M butyl carbonate Chemical compound CCCCOC([O-])=O DFFDSQBEGQFJJU-UHFFFAOYSA-M 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001175 calcium sulphate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
238000000451 chemical ionisation Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
239000000039 congener Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
210000003024 peritoneal macrophage Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical group OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
239000003726 plant lectin Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000004237 preparative chromatography Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
229910052701 rubidium Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002884 skin cream Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940043517 specific immunoglobulins Drugs 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
ZXLDQJLIBNPEFJ-UHFFFAOYSA-N tetrahydro-beta-carboline Natural products C1CNC(C)C2=C1C1=CC=C(OC)C=C1N2 ZXLDQJLIBNPEFJ-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical group CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Indole Compounds (AREA)

JP61000483A 1985-01-07 1986-01-06 テトラペプチド、その製造法およびそれらを含有する調剤組成物 Granted JPS61161298A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR8500140A FR2575753B1 (fr)	1985-01-07	1985-01-07	Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR8500140		1985-01-07

Publications (2)

Publication Number	Publication Date
JPS61161298A true JPS61161298A (ja)	1986-07-21
JPH0229080B2 JPH0229080B2 (2)	1990-06-27

Family

ID=9315046

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP61000483A Granted JPS61161298A (ja)	1985-01-07	1986-01-06	テトラペプチド、その製造法およびそれらを含有する調剤組成物

Country Status (15)

Country	Link
US (1)	US4720484A (2)
EP (1)	EP0190058B1 (2)
JP (1)	JPS61161298A (2)
AT (1)	ATE31537T1 (2)
AU (1)	AU578781B2 (2)
CA (1)	CA1270596A (2)
DE (1)	DE3660010D1 (2)
ES (1)	ES8707552A1 (2)
FR (1)	FR2575753B1 (2)
GR (1)	GR860023B (2)
IE (1)	IE58273B1 (2)
NZ (1)	NZ214722A (2)
OA (1)	OA08182A (2)
PT (1)	PT81793B (2)
ZA (1)	ZA86105B (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0348695A (ja) *	1989-06-29	1991-03-01	Adir	ペプチド誘導体
JPH04253995A (ja) *	1990-06-18	1992-09-09	Adir	新規ペプチド化合物

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2610934B1 (fr) *	1987-02-13	1989-05-05	Adir	Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2616663B1 (fr) *	1987-06-16	1989-08-18	Adir	Nouveaux tripeptides a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA1340588C (en) *	1988-06-13	1999-06-08	Balraj Krishan Handa	Amino acid derivatives
IE63490B1 (en) *	1988-11-24	1995-05-03	Hoechst Ag	Peptides having bradykinin antagonist action
US5648333A (en) *	1988-11-24	1997-07-15	Hoechst Aktiengesellschaft	Peptides having bradykinin antagonist action
US5028593A (en) *	1989-08-15	1991-07-02	Board Of Regents, The University Of Texas System	Tuftsin analogs
GB8927913D0 (en) *	1989-12-11	1990-02-14	Hoffmann La Roche	Amino acid derivatives
EP0454302A3 (en) *	1990-03-30	1992-10-14	Banyu Pharmaceutical Co., Ltd.	Tuftsin derivatives
US5391705A (en) *	1991-03-15	1995-02-21	Merrell Dow Pharmaceuticals Inc.	Polyfluorinated tripeptide thrombin inhibitors
US6177405B1 (en) *	1992-07-22	2001-01-23	Kenji Nishioka	Cyclic analogs of tuftsin
US5662885A (en) *	1994-07-22	1997-09-02	Resolution Pharmaceuticals Inc.	Peptide derived radionuclide chelators
AU708620B2 (en) *	1995-03-29	1999-08-05	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US6069232A (en) *	1995-10-02	2000-05-30	Hoechst Marion Roussel, Inc.	Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
US5739354A (en) *	1996-03-26	1998-04-14	Hoechst Marion Roussel, Inc.	Process for the preparation of N-methyl-D-phenylalanyl-N- 1- 3- (aminoiminomethyl)amino!propyl!-3,3-difluoro-2-oxohexyl!-L-prolinamide
AP1019A (en)	1996-10-18	2001-10-16	Vertex Pharma	Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
IL159087A0 (en) *	2001-07-11	2004-05-12	Vertex Pharma	Bridged bicyclic compounds and pharmaceutical compositions containing the same
CA2477391A1 (en) *	2002-03-01	2003-09-12	Denis Schrier	Method of treating osteoarthritis
UY28500A1 (es)	2003-09-05	2005-04-29	Vertex Pharma	Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
US7767689B2 (en) *	2004-03-15	2010-08-03	Ptc Therapeutics, Inc.	Carboline derivatives useful in the treatment of cancer
MXPA06010543A (es) *	2004-03-15	2007-03-26	Ptc Therapeutics Inc	Derivados de carbolina utiles en la inhibicion de la angiogenesis.
US8076353B2 (en) *	2004-03-15	2011-12-13	Ptc Therapeutics, Inc.	Inhibition of VEGF translation
US8076352B2 (en) *	2004-03-15	2011-12-13	Ptc Therapeutics, Inc.	Administration of carboline derivatives useful in the treatment of cancer and other diseases
WO2005094818A1 (en)	2004-03-23	2005-10-13	Genentech, Inc.	Azabicyclo-octane inhibitors of iap
RS52545B (sr)	2004-04-07	2013-04-30	Novartis Ag	Inhibitori protein apoptoze (iap)
BRPI0511350A (pt) *	2004-07-02	2007-12-04	Genentech Inc	composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
MX2007007195A (es) *	2004-12-20	2007-10-08	Genentech Inc	Inhibidores de pirrolidina de iap.
AU2006275413B2 (en) *	2005-08-02	2012-07-19	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
US7964624B1 (en) *	2005-08-26	2011-06-21	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
AR055395A1 (es)	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007106192A2 (en) *	2005-12-19	2007-09-20	Genentech, Inc.	Inhibitors of iap
AU2007217355B2 (en)	2006-02-27	2012-06-21	Vertex Pharmaceuticals Incorporated	Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
WO2007109080A2 (en) *	2006-03-16	2007-09-27	Vertex Pharmaceuticals Incorporated	Deuterated hepatitis c protease inhibitors
PE20110220A1 (es)	2006-08-02	2011-04-11	Novartis Ag	DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
MX2009002893A (es)	2006-09-18	2009-07-10	Raptor Pharmaceutical Inc	Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
US8063218B2 (en) *	2006-12-19	2011-11-22	Genentech, Inc.	Imidazopyridine inhibitors of IAP
WO2008106058A2 (en) *	2007-02-27	2008-09-04	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
HRP20120330T1 (hr) *	2007-02-27	2012-05-31	Vertex Pharmaceuticals Incorporated	Sukristali i farmaceutski pripravci koji ih sadrže
PE20130150A1 (es) *	2007-04-30	2013-02-27	Genentech Inc	Inhibidores de las iap
NZ583699A (en) *	2007-08-30	2012-04-27	Vertex Pharma	Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
ES2398791T3 (es) *	2008-01-11	2013-03-21	Genentech, Inc.	Inhibidores de IAP
CN102171209A (zh)	2008-08-02	2011-08-31	健泰科生物技术公司	Iap抑制剂
JP2012500272A (ja) *	2008-08-16	2012-01-05	ジェネンテック，インコーポレイテッド	Ｉａｐのアザインドールインヒビター
US20120077778A1 (en)	2010-09-29	2012-03-29	Andrea Bourdelais	Ladder-Frame Polyether Conjugates
JP6007262B2 (ja)	2012-01-06	2016-10-12	ノーバス・インターナショナル・インコーポレイテッドＮｏｖｕｓＩｎｔｅｒｎａｔｉｏｎａｌ，Ｉｎｃ．	スルホキシドベース界面活性剤
EP2812313A4 (en)	2012-02-09	2015-09-30	Novus Int Inc	FUNCTIONALIZED POLYMERIC COMPOSITIONS
MX2015000395A (es)	2012-07-12	2015-04-10	Novus Int Inc	Composiciones de matriz y capa para proteccion de bioactivos.
US10227551B2 (en)	2015-11-12	2019-03-12	Novus International, Inc.	Sulfur-containing compounds as solvents
US10584306B2 (en)	2017-08-11	2020-03-10	Board Of Regents Of The University Of Oklahoma	Surfactant microemulsions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5647895B2 (2) *	1973-06-08	1981-11-12
US4353823A (en) *	1981-09-01	1982-10-12	Chipens Gunar I	Synthetic analog of tuftisin

1985
- 1985-01-07 FR FR8500140A patent/FR2575753B1/fr not_active Expired
1986
- 1986-01-06 NZ NZ214722A patent/NZ214722A/xx unknown
- 1986-01-06 JP JP61000483A patent/JPS61161298A/ja active Granted
- 1986-01-06 AU AU51854/86A patent/AU578781B2/en not_active Ceased
- 1986-01-06 CA CA000499067A patent/CA1270596A/fr not_active Expired - Lifetime
- 1986-01-06 AT AT86400010T patent/ATE31537T1/de not_active IP Right Cessation
- 1986-01-06 IE IE2186A patent/IE58273B1/en not_active IP Right Cessation
- 1986-01-06 DE DE8686400010T patent/DE3660010D1/de not_active Expired
- 1986-01-06 PT PT81793A patent/PT81793B/pt not_active IP Right Cessation
- 1986-01-06 EP EP86400010A patent/EP0190058B1/fr not_active Expired
- 1986-01-07 OA OA58759A patent/OA08182A/xx unknown
- 1986-01-07 ZA ZA86105A patent/ZA86105B/xx unknown
- 1986-01-07 GR GR860023A patent/GR860023B/el unknown
- 1986-01-07 ES ES550716A patent/ES8707552A1/es not_active Expired
- 1986-11-20 US US06/933,093 patent/US4720484A/en not_active Expired - Fee Related

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0348695A (ja) *	1989-06-29	1991-03-01	Adir	ペプチド誘導体
JPH04253995A (ja) *	1990-06-18	1992-09-09	Adir	新規ペプチド化合物

Also Published As

Publication number	Publication date
IE860021L (en)	1986-07-07
CA1270596A (fr)	1990-06-19
US4720484A (en)	1988-01-19
AU5185486A (en)	1986-07-10
JPH0229080B2 (2)	1990-06-27
NZ214722A (en)	1988-09-29
ES550716A0 (es)	1987-08-01
DE3660010D1 (en)	1988-02-04
PT81793A (fr)	1986-02-01
EP0190058B1 (fr)	1987-12-23
PT81793B (pt)	1988-05-27
OA08182A (fr)	1987-10-30
ES8707552A1 (es)	1987-08-01
ZA86105B (en)	1986-10-29
AU578781B2 (en)	1988-11-03
FR2575753A1 (fr)	1986-07-11
ATE31537T1 (de)	1988-01-15
GR860023B (en)	1986-05-06
FR2575753B1 (fr)	1987-02-20
IE58273B1 (en)	1993-08-25
EP0190058A1 (fr)	1986-08-06

Publication	Publication Date	Title
JPS61161298A (ja)	1986-07-21	テトラペプチド、その製造法およびそれらを含有する調剤組成物
EP0517589B1 (fr)	1996-12-27	Dérivés de tachykinines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
IE50261B1 (en)	1986-03-19	Antihypertensive amides
JPS59500863A (ja)	1984-05-17	ゴナドリベリン誘導体、その製造方法及びその医薬及び獣医薬組成物
JPH01151600A (ja)	1989-06-14	シクロスポリン
CA1318457C (en)	1993-05-25	Partially retro-inverted tuftsin analogues, method for the preparation thereof and pharmaceutical compositions containing them
FR2460291A1 (fr)	1981-01-23	Nouveaux tripeptides agissant sur le systeme nerveux central et leur procede de preparation
JPS63203698A (ja)	1988-08-23	多環状窒素含有構造を有する新規なペプチド誘導体
JPS6233198A (ja)	1987-02-13	新規なペプチド誘導体
JPH0559105B2 (2)	1993-08-30
US5047400A (en)	1991-09-10	Tripeptide compounds having a nitrogenous polycyclic structure
JPH09503200A (ja)	1997-03-31	Ｃ反応性タンパク質断片から誘導されたオリゴペプチド
JPS5973551A (ja)	1984-04-25	ペプチド及びプソイドペプチド誘導体、その製造法及びこれを含有し選択的阿片剤δ受体「きつ」抗性製薬組成物
JPS60231697A (ja)	1985-11-18	ペプチド
JPS61191695A (ja)	1986-08-26	新規ペプタイド
JPS5951935B2 (ja)	1984-12-17	新規なペプチドおよびその製造法
EP0205209B1 (en)	1989-11-29	Decapeptides having hypotensive action and process for their preparation
EP0607647A1 (en)	1994-07-27	N-Methyldeacetylcolchiceinamide derivatives
US5137917A (en)	1992-08-11	Spergualin-related compound and use thereof
Chen et al.	1975	Synthesis of di-and tripeptides containing 4-aminocyclohexanecarboxylic acid
US20070037845A1 (en)	2007-02-15	Peptido-mimetic compounds containing rgd sequence useful as integrin inhibitors, and intermediates thereof
GB2127831A (en)	1984-04-18	Intermediates in the preparation of caerulein
JPS6042399A (ja)	1985-03-06	マイコプラネシン誘導体
HK1005857A1 (en)	1999-01-29	2-(n-acyl)amino-6,7-dimethoxy tetralines, process for their preparation and pharmaceutical compositions having antihypertensive activity containing same

JPS61161298A - テトラペプチド、その製造法およびそれらを含有する調剤組成物 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (2)

Family

ID=9315046

Family Applications (1)

Country Status (15)

Cited By (2)

Families Citing this family (49)

Family Cites Families (2)

Cited By (2)

Also Published As

Similar Documents